Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783951 | 0.88 | MEN1 (0.36) | FGFR1MEN1KMT2AFGFR4KDR | |
| SCHEMBL23328260 | 0.86 | MEN1 (0.35) | FGFR1SRCMEN1KMT2AFGFR4 | |
| SCHEMBL22396654 | 0.85 | FGFR1 (0.42) | FGFR1SRCDHFRFGFR4 | |
| SCHEMBL16072038 | 0.81 | FGFR1 (0.71) | FGFR1FGFR4KDRFYN | |
| SCHEMBL31648203 | 0.81 | FGFR1 (0.71) | FGFR1FGFR4KDRFYN | |
| SCHEMBL23328278 | 0.79 | FGFR1 (0.34) | FGFR1MEN1KMT2AFGFR4KDR | |
| SCHEMBL31648322 | 0.79 | FGFR1 (0.45) | FGFR1SRCDHFRKDRFYN | |
| SCHEMBL23328261 | 0.77 | FGFR1 (0.42) | FGFR1FGFR4KDR | |
| SCHEMBL23328284 | 0.76 | FGFR1 (0.39) | FGFR1FGFR4KDR | |
| SCHEMBL29545501 | 0.76 | FGFR1 (0.38) | FGFR1MEN1KMT2AFGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210340142-A1 | SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2021-11-04 | — | — | US | disclosed |
| EP-3845534-A1 | SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-07-07 | — | — | EP | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| WO-2020043078-A1 | SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF | 贝达药业股份有限公司 | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340142-A1 | SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF | CS, MDH2, MDH1 | FGFR1 471/4885PTPN11 325/4885SRC 802/4885 |
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | FGFR1 1/4885PTPN11 138/4885SRC 91/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | FGFR1 1/4885PTPN11 116/4885SRC 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.